JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 23, 2004; DOI: 10.1124/jpet.103.062760


0022-3565/04/3092-523-532$20.00
JPET 309:523-532, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.062760v1
309/2/523    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Struckhoff, A. P.
Right arrow Articles by Beckman, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Struckhoff, A. P.
Right arrow Articles by Beckman, B. S.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer

Amanda P. Struckhoff, Robert Bittman, Matthew E. Burow, Sanda Clejan, Steven Elliott, Timothy Hammond, Yan Tang, and Barbara S. Beckman

Departments of Pharmacology (A.P.S., B.S.B.), Pathology (S.C.), and Medicine (T.H., M.E.B.), Molecular and Cellular Biology Program (M.E.B., S.C., S.E., Y.T., B.S.B.), Center for Bioenvironmental Research (M.E.B., S.C., S.E., Y.T., B.S.B.), Tulane Cancer Center (M.E.B., S.E., Y.T., B.S.B.), and Louisiana General Clinical Research Center (S.C.), Tulane University Health Sciences Center, New Orleans, Louisiana; Department of Chemistry and Biochemistry, Queens College, City University of New York, Flushing, New York (R.B.); and Veterans Affairs Medical Center, New Orleans, Louisiana (T.H.)

Recent evidence suggests a role for aberrant ceramide levels in the pathogenesis of cancer and chemoresistance and indicates that manipulation of tumor ceramide levels may be a useful strategy in the fight against breast cancer. This study demonstrates that alterations in the degree and position of unsaturation of bonds in the sphingoid backbone of D-erythro-N-octanoyl-sphingosine (Cer) affect the antiproliferative ability of ceramide analogs in breast cancer cells. The most potent analog of Cer we tested is (2S,3R)-(4E,6E)-2-octanoylamidooctadecadiene-1,3-diol (4,6-diene-Cer), which contains an additional trans double bond at C(6)-C(7) of the sphingoid backbone. 4,6-Diene-Cer exhibited higher potency than Cer in tumor necrosis factor (TNF)-{alpha}-resistant (IC50 of 11.3 versus 32.9 µM) and TNF-{alpha}-sensitive (IC50 of 13.7 versus 37.7 µM) MCF-7 cells. 4,6-Diene-Cer was also more potent than Cer in inducing cell death in MDA-MB-231 and NCI/ADR-RES breast cancer cell lines (IC50 of 3.7 versus 11.3 µM, and 24.1 versus 86.9 µM, respectively). 4,6-Diene-Cer caused a prolonged elevation of intracellular ceramide levels in MCF-7 cells, which may contribute to its enhanced cytotoxicity. Furthermore, treatment of MCF-7 cells with Cer or 4,6-diene-Cer resulted in induction of apoptosis by 8 h via the mitochondrial pathway, as demonstrated by release of cytochrome c, loss of membrane asymmetry (measured by Annexin V staining), and a decrease in the mitochondrial membrane potential. Importantly, both Cer and 4,6-diene-Cer displayed selectivity toward transformed breast cells over nontransformed breast epithelial cells. These data suggest that these and other novel ceramide analogs represent potential therapeutic agents in breast cancer treatment.


Received November 11, 2003; accepted January 21, 2004.

Address correspondence to: Dr. Barbara S. Beckman, Department of Pharmacology, Tulane Health Sciences Center, 1430 Tulane Ave. SL-83, New Orleans, LA 70112. E-mail: bbeckman{at}tulane.edu




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
S. T. Pruett, A. Bushnev, K. Hagedorn, M. Adiga, C. A. Haynes, M. C. Sullards, D. C. Liotta, and A. H. Merrill Jr.
Thematic Review Series: Sphingolipids. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols
J. Lipid Res., August 1, 2008; 49(8): 1621 - 1639.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. E. Senkal, S. Ponnusamy, M. J. Rossi, K. Sundararaj, Z. Szulc, J. Bielawski, A. Bielawska, M. Meyer, B. Cobanoglu, S. Koybasi, et al.
Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1188 - 1199.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. C. Stover, A. Sharma, G. P. Robertson, and M. Kester
Systemic Delivery of Liposomal Short-Chain Ceramide Limits Solid Tumor Growth in Murine Models of Breast Adenocarcinoma
Clin. Cancer Res., May 1, 2005; 11(9): 3465 - 3474.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
H. L. Brockman, M. M. Momsen, R. E. Brown, L. He, J. Chun, H.-S. Byun, and R. Bittman
The 4,5-Double Bond of Ceramide Regulates Its Dipole Potential, Elastic Properties, and Packing Behavior
Biophys. J., September 1, 2004; 87(3): 1722 - 1731.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.